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original work is propIntroduction: Using the data of a trial on cotrimoxazole (CTX) cessation, we investi-
gated the effect of different antiretroviral therapy (ART) regimens on the incidence of
clinical malaria.
Methods: During the cotrimoxazole cessation trial (ISRCTN44723643), HIV-infected
Ugandan adults with CD4þ at least 250 cells/ml were randomized to receive either CTX
prophylaxis or placebo and were followed for a median of 2.5 years. Blood slides for
malariamicroscopywere examined at scheduled visits and at unscheduled visits when
the participant felt unwell. CD4þ cell counts were done 6-monthly. Malaria was
defined as fever with a positive blood slide. ART regimens were categorized as
nucleoside reverse transcriptase inhibitor (NRTI) only, non-nucleoside reverse tran-
scriptase inhibitor (NNRTI)-containing or protease inhibitor containing. Malaria
incidence was calculated using random effects Poisson regression to account for
clustering of events.
Results: Malaria incidence in the three ART regimen groups was 9.9 (3.6-27.4),
9.3 (8.3-10.4), and 3.5 (1.6-7.6) per 100 person-years, respectively. Incidence on
protease inhibitorswas lower than that on the other regimenswith the results just reaching
significance (adjusted rate ratio 0.4, 95% confidence interval¼0.2–1.0, comparingwith
NNRTI regimens). Stratification by CTX/placebo use gave similar results, without evi-
dence of an interaction between the effects of CTX/placebo use and ART regimen. There
was no evidence of an interaction between ART regimen and CD4þ cell count.
Conclusion: There was some evidence that protease inhibitor-containing ART regi-
mens may be associated with a lower clinical malaria incidence compared with other
regimens. This effect was not modified by CTX use or CD4þ cell count. The antimalarial
properties of protease inhibitors may have clinical and public health importance.
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Fig. 1. Time to occurrence of first malaria event by ART
regimen. ART, antiretroviral therapy; NNRTI, non-nucleoside
reverse transcriptase inhibitor; NRTI, nucleoside reverse tran-
scriptase inhibitor; PI, protease inhibitor.Antiretroviral therapy (ART) is used to control HIV
replication in infected patients [1,2]. In addition, some
ART drugs, particularly protease inhibitors, have shown
antimalaria properties in vitro [3–5]. In children, a
randomized clinical trial showed that use of protease
inhibitor ART was associated with a lower risk of
recurrent malaria compared with non-nucleoside reverse
transcriptase (NNRTI)-based ART [6]. However, a study
of HIV infected adult women found no beneficial effect
of lopinavir/ritonavir compared with nevirapine on
malaria incidence [7]. Studies on protease inhibitor use in
the general adult population are lacking.
The present study undertook a subanalysis of data
collected in the COSTOP (cotrimoxazole cessation) trial
(ISRCTN44723643), a study designed to investigate the
safety of stopping cotrimoxazole (CTX) in HIV-infected
adults stable on ART, to assess whether malaria incidence
differed between participants receiving different ART
regimens and whether any such effects were modified by
CTX use or CD4þ cell count.Methods
The study was conducted among COSTOP trial
participants in Uganda, a country with high malaria
endemicity [8,9]. COSTOP has been described previously
[10,11]. In brief, this randomized placebo controlled
noninferiority trial was conducted between 2011 and 2014
to determine whether prophylaxis with CTX can be safely
discontinued among HIV infected adults on ART with
CD4þ cell counts at least 250 cells/ml.
Participants were followed every month for the first 3
months and 3-monthly, thereafter, for a median of 2.5
years. At enrolment participants were provided with an
insecticide-treated bed net. Blood samples for malaria
microscopy were collected at scheduled visits and
unscheduled visits if malaria was suspected. CD4þ cell
counts were done 6-monthly. Participants diagnosed with
malaria were treated in accordance with the national
guidelines [12]. Participants were encouraged to return to
the study clinics if they felt unwell, those treated
elsewhere were asked to present documentary evidence
of diagnoses: if no documentation was available this was
not considered a confirmed case. Malaria for this analysis
was defined as a history of fever with parasitaemia on
blood slide. Presumptive malaria cases (blood slide
negative or not done) were not included.
Information on participants’ ART regimens at ART
initiation and at enrolment was obtained from the records
of the ART providers from where participants were
recruited. During the trial, participants continued to
receive ART from their usual providers, but trial staff Copyright © 2017 Wolters Kluwer Hensured an uninterrupted supply of ART in case of
unexpected shortages. Most participants were on an
NNRTI-containing regimen (recommended first-line
regimen in Uganda) [13], the remainder of participants
were on regimens as outlined in Fig. 1.
Blood samples were used to prepare thick and thin films
on a glass slide. Specimens were processed using
Leishman’s stain and examined by microscopy. Venous
blood samples were taken for CD4þ cell counts and
measured using a FACS-count system (Becton-Dick-
inson, San Jose, California USA).
Analysis
Data were double entered and verified in MS Access and
analysed using Stata, release 13 (StataCorp LP, College
Station, Texas USA). Person years at risk were calculated
from enrolment until the date last seen or end of trial.
After each malaria episode, participants were considered
to be not at risk for another episode until the episode
resolved, or for 28 days, if a resolution date was not
available. The time to the first malaria episode was
examined using Kaplan–Meier methods and log rank
tests to compare between groups. The incidence of
malaria and rate ratios comparing ART regimens were
calculated using random effects Poisson regression to
account for multiple episodes within the same partici-
pant. Models were adjusted for treatment group (CTX
or placebo), enrolment site, and time since enrolment as
a priori confounders. ARTregimens were categorized as
NRTI (nucleoside reverse transcriptase) only, if a
regimen containing only NRTIs was used; NNRTI
containing, if one of the drugs was an NNRTI and none
was a protease inhibitor; or protease inhibitor contain-
ing, if at least one drug was a protease inhibitor. ART
regimen was analysed as a time-updated exposure. The
effect of ART regimen on malaria incidence wasealth, Inc. All rights reserved.
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groups; stratified rate ratios were obtained from a model
containing a term for interaction between treatment
group and ARTregimen. Analyses were also stratified by
current CD4þ cell count (<500 or 500) to assess
whether the effect of ART regimen on malaria differed
by CD4þ cell count.Results
Baseline characteristics have been described previously
[11]. Briefly, the trial enrolled 2180 participants: 1002 in
Entebbe and 1178 in Masaka. Half (1089) were
randomised to CTX (stratified by site), 382 (18%) had
CD4þ cell count less than 350 cells/ml at enrolment, and
569 (26%) were male. In total, 1721 (79%) participants
had been on ART for at least 2 years. At the time of ART
initiation, 2114 (97%) started on an NNRTI-containing
regimen, 58 (3%) on an NRTI-only regimen, and three
on a protease inhibitor -containing regimen; data were
missing for five participants. At enrolment, 2046 (94%)
were on an NNRTI containing regimen, 22 (1%) on an
NRTI-only regimen and 86 (4%) on a protease inhibitor-
containing regimen; enrolment ART information was
missing for 26 participants (1%). Of those on a protease Copyright © 2017 Wolters Kluwe
Table 1. Incidence of malaria by ART regimen overall and stratified by t
ART regimena Events P
NNRTI containing 435
NRTI only 5
PI containing 7
Stratified by treatment arm
CTX NNRTI containing 97
NRTI only 1
PI containing 2
Placebo NNRTI containing 338
NRTI only 4
PI containing 5
Stratified by current CD4þ cell count
CD4þ <500 NNRTI containing 200
NRTI only 2
PI containing 4
CD4þ 500 NNRTI containing 235
NRTI only 3
PI containing 3
ART, antiretroviral therapy; CTX, cotrimoxazole; NNRTI, non-nucleoside rev
inhibitor.
aNNRTI containing was defined as a regimen that contained at least one N
NRTIs; PI containing was defined as a regimen in which at least one of th
bestimated from random effects Poisson regression.
cadjusted for treatment arm, site, and time since enrolment.
dP value for effect of ART regimen, from likelihood ratio test (LRT).
eLRT for interaction between treatment arm and ART regimen, and betwe
fP value from the Wald test.inhibitor-containing regimen, 75 (87%) were on
lopinavir/ritonavir, 4 (5%) on atanazavir and 7 (8%)
on another protease inhibitor. Of those on an NNRTI,
2066 (88%) were on nevirapine, 255 (12%) on efavirenz,
and two on etravine. In total, 10 participants changed
ART regimen during follow-up (nine NNRTI contain-
ing, one NRTI only); all changes were to a protease
inhibitor-containing regimen (six to lopinavir/ritonavir,
three to atanazavir and one to another protease
inhibitor).
Effect of antiretroviral therapy regimen
In total, 2154 participants contributed data to the analysis;
447 malaria episodes were observed during follow-up, of
which 40 (8%) were diagnosed outside the study clinic.
There was some evidence that time to the first malaria
episode was shorter for participants on an NNRTI-
containing or NRTI-only regimen compared with those
on a protease inhibitor-containing regimen (P¼ 0.05;
Fig. 1). In the unadjusted analysis, malaria incidence was
similar for participants on NRTI-only compared with
participants on a NNRTI-containing regimen, and was
lower for participants on a protease inhibitor regimen
compared with participants on an NNRTI (Table 1).
After adjustment for treatment group, enrolment site and
time since enrolment, malaria incidence among partici-
pants on an NRTI-only regimen was 1.6 (0.6–4.3) timesr Health, Inc. All rights reserved.
reatment arm and current CD4R stratum.
erson years Rateb Rate ratiob Rate ratiob,c
P¼0.02d P¼0.05b,d
4737 9.3 (8.3–10.4) 1 1
50 9.9 (3.6–27.4) 1.1 (0.4–3.0) 1.6 (0.6–4.3)
202 3.5 (1.6–7.6) 0.4 (0.2–0.8) 0.4 (0.2–1.0)
P¼0.92e P¼0.95e
P¼0.62f P¼0.64f
2380 4.1 (3.3–5.0) 1 1
25 4.2 (0.5–32.1) 1.0 (0.1–8.0) 1.5 (0.2–11.8)
100 2.0 (0.5–8.2) 0.5 (0.1–2.0) 0.5 (0.1–2.3)
P¼0.07f P¼0.11f
2357 14.5 (12.9–16.4) 1 1
25 15.4 (4.9–48.0) 1.1 (0.3–3.3) 1.6 (0.5–5.0)
102 5.0 (2.0–12.4) 0.3 (0.1–0.9) 0.4 (0.2–1.0)
P¼0.86e P¼0.96e
P¼0.21f P¼0.30f
2358 8.6 (7.5–10.1) 1 1
33 7.0 (1.5–32.0) 0.8 (0.2–3.7) 1.4 (0.3–6.1)
118 3.5 (1.2–9.6) 0.4 (0.1–1.1) 0.5 (0.2–1.3)
P¼0.21f P¼0.24f
2379 9.9 (8.6–11.5) 1 1
17 13.9 (3.6–54.4) 1.4 (0.4–5.5) 1.8 (0.5–6.6)
84 3.5 (1.1–11.6) 0.4 (0.1–1.2) 0.4 (0.1–1.4)
erse transcriptase; NRTI, nucleoside reverse transcriptase; PI, protease
NRTI and no PI; NRTI only was defined as a regimen containing only
e drugs was a PI.
en treatment arm and CD4þ cell count group.
580 AIDS 2017, Vol 31 No 4higher than among those on an NNRTI-containing
regimen, whereas that among participants on a protease
inhibitor-containing regimen was 0.4 (0.2–1.0) times
lower (P¼ 0.05; Table 1).
In the adjusted analysis stratified by treatment group,
malaria incidence among participants on an NRTI-only
regimen was 1.5 (0.2–11.8) (CTX) and 1.6 (0.5–5.0)
(placebo) times higher than those on an NNRTI-
containing regimen, whereas that in participants on a
protease inhibitor-containing regimen was 0.5 (0.1–2.3)
(CTX) and 0.4 (0.2–1.0) (placebo) times lower,
respectively. There was no evidence of interaction
between the effect of treatment group and ART regimen
(P¼ 0.95; Table 1). Rate ratios were similar in the analysis
stratified by current CD4þ cell count, with no evidence
of interaction between the effect of CD4þ cell count and
ART regimen (P¼ 0.96; Table 1).Discussion
Protease inhibitor-containing regimens are recom-
mended as second-line therapy for adults in Uganda
and elsewhere [13,14] and were used by 4% of participants
in this study. The most commonly used protease inhibitor
was lopinavir/ritonavir. In total, 1% of participants were
on an NRTI-only regimen, an alternative initial regimen
recommended at the time [2,15].
We found that NRTI-only regimens provided the least
protection against malaria followed by NNRTI-contain-
ing regimens. This is consistent with in-vitro studies that
showed no antimalarial activity from NRTIs and some
activity from NNRTIs but at levels which were not
achievable in vivo at standard dosing [3,16]. Use of a
protease inhibitor-containing regimen was associated
with the strongest protection (rate ratio 0.4; 95%
confidence interval¼ 0.2–1.0 P¼ 0.05, compared with
NNRTI-containing regimens) and this is consistent with
findings of a study in children [6].
We have previously reported that CTX use is associated
with reduced incidence of malaria [17], an association
that has been reported by other studies [18–20]. We
did not find evidence of potentiation/interaction
between the antimalarial effects of CTX and protease
inhibitors.
In a study in children, the effect of protease inhibitors on
malaria was partially attributed to a reduction in malaria
recurrence as a result of increased lumefantrine levels after
treatment, owing to cytochrome P450 enzyme inhibition
by lopinavir/ritonavir [6]. These findings are in line with
pharmacokinetic studies that have reported increased
lumefantrine levels, in patients concomitantly taking
lopinavir–ritonavir-based ART [21–24]. We did not
measure drug levels during follow-up but we found that Copyright © 2017 Wolters Kluwer Hthe time to first malaria episode (i.e., before malaria
treatment) was longer for participants on a protease
inhibitor-containing regimen implying that in adults, the
observed effect might be because of a direct effect of
protease inhibitors on Plasmodium proteases rather than
drug–drug interactions with lumefantrine.
These findings are potentially of benefit. It has been
suggested that the antimalarial prophylactic effect of
protease inhibitor-containing ART regimens could
reduce the cost of care in malaria endemic countries
because of a potential reduction in malaria treatment costs
[25], could help reduce the prevalence of malaria [26],
could help reduce malaria transmission because of their
gametocytocidal effect [27,28] and could even contribute
to malaria eradication because lopinavir inhibits Plasmo-
dium falciparum liver stage parasites [29], further clinical
studies are, however, needed. Despite the lack of an
antimalarial effect at therapeutic doses, benefits of
NNRTI use, which include ease of dosing (because of
combination pills), easier storage, better tolerability, and
lower cost, should still make NNRTIs the preferred first-
line choice in adults in malaria endemic areas [15,30].
However, clinicians may want to consider the added
antimalarial benefit of using protease inhibitors when
treating high-risk groups, for example, pregnant women,
or when prescribing malaria prophylaxis in those on
second-line therapy.
Strength and limitations
Our study benefited from a well described study
population that was followed regularly for up to 3.5
years and routinely assessed for malaria. However,
although this offered an opportunity to investigate the
effect of ARTregimen on malaria, the COSTOP trial was
not specifically designed to address this question. The
number of participants on protease inhibitors was small,
the observed protective effect just reached statistical
significance, and therefore we cannot exclude the
possibility that the effects might have occurred because
of chance. As participants on protease inhibitors were on
second-line therapy, their clinical condition may be
different from those on first-line therapy; we were not
able to adjust for potential confounders relating to
individual health status. A history of fever (within
previous 2 weeks) and parasitaemia were the basis for
malaria diagnosis, this could have resulted in over-
estimation of cases, however 92% of cases were diagnosed
by the study team, allowing for ascertainment of most
diagnoses. Adherence to ART in our study population
was high [11]. However, as we did not determine viral
load or serum levels of ART drugs during follow-up, our
findings may be subject to potential residual confounding
resulting from differences in adherence between
ART groups.
In conclusion, among HIV infected adults on ART,
protease inhibitor-containing regimens were associatedealth, Inc. All rights reserved.
Effect of antiretroviral therapy regimen on malaria Kasirye et al. 581with reduced clinical malaria incidence compared with
NNRTI-containing or NRTI-only regimens. The
antimalarial properties of protease inhibitors may have
clinical and public health importance.Acknowledgements
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